Welcome to THAOS

Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Plante V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H,
Said G. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation.
Brain 123 (Pt. 2000; 7): 1495–504.

Alves IL, Hays MT, Saraiva MJM. Comparative stability and clearance of [Met30]transthyretin and [Met119]
transthyretin. Eur J Biochem. 1997; 249: 662–8.

Ando Y. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Amyloid 10 Suppl. 2003; 1: 55–66.

Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005; 62: 1057–62.

Augustin S, Llige D, Andreu A, González A, Genescà J. Familial amyloidosis in a large Spanish kindred resulting from a D38V
mutation in the transthyretin gene. Eur J Clin Invest. 2007 Aug;37 (8):673-8.

Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007 Oct; 36(4):411-23.

Brett M, Persey MR, Reilly MM, Revesz T, Booth DR, Booth SE, Hawkins PN, Pepys MB, Morgan-Hughes JA. Transthyretin Leu12Pro
is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 122 (Pt. 1999; 2): 183–90.

Coelho T, Chorao R, Sousa A, Alves IL, Torres MF, Saraiva MJ. Compound heterozygote of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloidotic polyneuropathy. Neuromusc Disord. 1996; 6: 20.

Coelho T, Sousa A, Lourenco E, Ramalheira J. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet. 1994; 31: 293–9.

Coutinho CA, Conceicao I, Almeida A, Cantinho G, Sargento L, Vagueiro MC. Early detection of sympathetic myocardial denervation in patients with familial amyloid polyneuropathy type I. Rev Port Cardiol. 2004; 23: 201–11.

Drugge U, Andersson R, Chizari F, Danielsson M, Holmgren G, Sandgren O, Sousa A. Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis. J Med Genet. 1993; 30: 388–92.

Ericzon B-G, Holmgren G, Lundgren E, Suhr OB. New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders and the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umea Sweden, June 1999. Amyloid: Int J Exp Clin Invest. 2000; 7: 145–7.

Haagsma EB, Hawkins PN, Benson MD, Lachmann HJ, Bybee A, Hazenberg BP. Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid. 2004; 11: 44–9.

Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid. 2003; 10: 229–39.

Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004; 77: 64–71.

Holmgren G, Ando Y, Wikstrom L. Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP) (TTR met30). Amyloid: Int J Exp Clin Invest. 1997; 4: 178–80.

Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, Nylander PO, Teixeira A, Saraiva MJ, Costa PP. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994; 31: 351–4.

Hornsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation. 2004; 78: 112–6.

Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007 Apr;274 (7):1637-50.

Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology. 2001; 56: 431–5.

Ikeda K, Kano O, Ito H, Kawase Y, Iwamoto K, Sato R, Sekine T, Nagata R, Nakamura Y, Hirayama T, Iwasaki Y. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2008 Apr 22;70 (17):1576

Ikeda S, Hanyu N, Hongo M, Yoshioka J, Oguchi H, Yanagisawa N, Kobayashi T, Tsukagoshi H, Ito N, Yokota T. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain 110 (Pt. 1987; 2): 315–37.

Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology. 2002; 58: 1001–7.

Ikeda S, Takei Y, Hashikura Y. Liver transplantation as treatment for neurological disorders. Expert Rev Neurotherapeutics. 2003; 3: 547–55.

Ikeda S, Takei Y, Yanagisawa N, Matsunami H, Hashikura Y, Ikegami T, Kawasaki S. Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. Ann Intern Med. 1997; 127: 618–20.

Juneblad K, Naslund A, Olofsson BO, Suhr OB. Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation. Amyloid. 2004; 11: 208–13.

Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, Shibata-Hamaguchi A, Furukawa Y, Yanase D, Ishida C, Sakajiri K, Yamada M. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci. 2008 Jul 15;270 (1-2):133-40

Kawaji T, Ando Y, Ando E, Nakamura M, Hirata A, Tanihara H. A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. Amyloid. 2004; 11: 257–9.

Liu YT, Lee YC, Yang CC, Chen ML, Lin KP. Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression. J Neurol Sci. 2008 Apr 15;267 (1-2):91-9.

Lobato L, Beirao I, Silva M, Fonseca I, Queiros J, Rocha G, Sarmento AM, Sousa A, Sequeiros J. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid. 2004; 11: 27–37.

Mascalchi M, Salvi F, Pirini MG, D'Errico A, Ferlini A, Lolli F, Plasmati R, Tessa C, Villari N, Tassinari CA. Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology. 1999; 53: 1498–503.

Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004; 84: 545–52.

Misu K, Hattori N, Ando Y, Ikeda S, Sobue G. Anticipation in early - but not late-onset familial amyloid polyneuropathy (TTR Met30) in Japan. Neurology. 2000; 55: 451–2.

Misu K, Hattori N, Nagamatsu M, Ikeda Si, Ando Y, Nakazato M, Takei Yi, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30- associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 122 (Pt. 1999; 10): 1951–62.

Motozaki Y, Sugiyama Y, Ishida C, Komai K, Matsubara S, Yamada M. Phenotypic heterogeneity in a family with FAP due to a TTR Leu58Arg mutation: a clinicopathologic study.
J Neurol Sci. 2007 Sep 15;260 (1-2):236-9.

Munar-Ques M, Lopes Dominguez JM, Viader-Farre C, Moreira P, Saraiva MJ. Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene. Amyloid. 2001; 8: 121–3.

Munar-Ques M, Pedrosa JL, Coelho T, Gusmao L, Seruca R, Amorim A, Sequeiros J. Two pairs of proven monozygotic twins discordant for familial amyloid neuropathy (FAP) TTR-Met30. J Med Genet. 1999; 36: 629–32.

Nagasaka T., Togashi S., Watanabe H., Iida H., Nagasaka K., Nakamura Y., Miwa M., Kobayashi F., Shindo K., Shiozawa Z. Clinical and histopathological features of progressive-type familial amyloidotic polyneuropathy with TTR Lys54. Journal of the Neurological Sciences. 2009. Volume 276, Issue 1: 88-94

Nakazato M. Genotype-phenotype relationship in familial amyloid polyneuropathy. Neurol Med (Tokyo). 1998; 48: 528–34.

Pérez G, Romero MC, Trigo P, Lendoire J, Imventarza O, Nesse A. Diagnosis of familial amyloid polyneuropathy type I in Argentina. Medicina (B Aires). 2008;68(4):273-81.

Pilato E, Dell'Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac Surg. 2007 Jul;32 (1):180-2.

Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007 Aug 14;69 (7):693-8.

Plante-Bordeneuve V, Said G. Transthyretin related familial amyloid polyneuropathy. Curr Opin Neurol. 2000; 13: 569–73.

Plante-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, Said G. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology. 1998; 51: 708–14.

Reilly MM, Adams D, Booth DR, Davis MB, Said G, Laubriat-Bianchin M, Pepys MB, Thomas PK, Harding AE. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain 118 (Pt. 1995; 4): 849–56.

Reilly MM, Adams D, Davis MB, Said G, Harding AE. Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (met 30 and tyr 77). J Neurol. 1995; 242: 664–8.

Saraiva MJ. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev Mol Med. 2002; 2002: 1–11.

Sekijima Y, Hammarstrom P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest. 2003; 83: 409–17.

Sekijima Y, Tokuda T, Kametani F, Tanaka K, Maruyama K, Ikeda S. Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid. 2001; 8: 257–62.

Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered. 1993; 43: 288–94.

Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet. 1995; 60: 512–21.

Sousa MM, Ferrao J, Fernandes R, Guimaraes A, Geraldes JB, Perdigoto R, Tome L, Mota O, Negrao L, Furtado AL, Saraiva MJ. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest. 2004; 84: 865–73.

Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol. 2004; 17: 615–20.

Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, O Grady J, Pepys MB, Williams R. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998; 66: 229.

Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005; 352: 2356.

Takei Y, Ikeda S, Hashikura Y, Ikegami T, Kawasaki S. Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. Ann Intern Med. 1999; 131: 592–5.

Tashima K, Ando Y, Tanaka Y, Uchino M, Ando M. Change in the age of onset in patients with familial amyloidotic polyneuropathy type I. Intern Med. 1995; 34: 748–50.

Tojo K, Sekijima Y, Machida K, Tsuchiya A, Yazaki M, Ikeda S. Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy. Muscle Nerve. 2008 Jun; 37(6):796-803.

Tokuda T, Takei Y, Takayama B, Hoshii Y, Ikeda S. Severe amyloid deposition in mammary glands of familial amyloid polyneuropathy patients. Amyloid. 2007 Sep;14 (3):249-53.

Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl. 2008 Apr;14 (4):563-70

Vita G, Mazzeo A, Di Leo R, Ferlini A. Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscul Disord. 2005; 15: 259–61.

Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A. Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. J Peripher Nerv Syst. 2004; 9: 232–41.

Yamamoto K, Ikeda S, Hanyu N, Takeda S, Yanagisawa N. A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy. J Med Genet. 1998; 35: 23–30.

Yoshinaga T, Takei Y, Katayanagi K, Ikeda S. Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene. Amyloid. 2004; 11: 56–60.

Yoshioka K, Furuya H, Sasaki H, Saraiva MJ, Costa PP, Sakaki Y. Haplotype analysis of familial amyloidotic polyneuropathy. Evidence for multiple origins of the Val-to-Met mutation most common to the disease. Hum Genet. 1989; 82: 9–13.

Zaros C, Genin E, Hellman U, Saporta MA, Languille L, Wadington-Cruz M, Suhr O, Misrahi M, Planté-Bordeneuve V. On the origin of the transthyretin Val30Met familial amyloid polyneuropathy. Ann Hum Genet. 2008 Jul;72(Pt 4):478-84.